Gilead Sciences, Inc. (Nasdaq: GILD) announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States.
Long-time liver specialist Carrie Frenette says she won’t ever forget the people she treated for hepatitis C (HCV) before 2013 – the year that the Food and Drug Administration (FDA) approved a Gilead medicine. The medicine was the first curative therapy for HCV.
The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer – and the challenges they face due to stigma and health inequities – come together in the form of a new, intentionally difficult-to-read book from Gilead.
When employees at Gilead’s recently opened New Jersey office need a place to meet, the “Cara” conference room is one such place they gather. Given the room’s namesake, it’s especially fitting when the topic at hand is the company’s oncology work.
Gilead Sciences, Inc. (Nasdaq: GILD) announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year.